ERBB2 and neoplasm: Loss of HER2 was demonstrated to result in a more mesenchymal phenotype, in which cells obtain an enhanced migratory capacity, resulting in a more aggressive tumor cell behavior, and the development of metastatic disease, contributing to a poor patient survival [23, 24].